Search
Donepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalIn 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. … [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.
Mixtures: EUTEBROL-DUO, EBICOMB 5 MG/5 MG EFERVESAN TABLET, 10 ADETCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 Substrates2-heptyl-4-hydroxyquinoline N-oxide
go.drugbank.com/drugs/DB07918ExperimentalCategories: Heterocyclic Compounds, 2-RingSynonyms: 2-heptyl-4-quinolinol 1-oxide, 2-(n-heptyl)-4-hydroxyquinoline N-oxideLumiliximab
go.drugbank.com/drugs/DB06162InvestigationalLumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. … It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions.
Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMERDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers. … Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery
Mixtures: DUEDOM 30/10 MG KAPSÜL, 30 ADET, DUEDOM 60/10 MG KAPSÜL, 30 ADETCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesNebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigationalNebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. … [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].
Mixtures: AMLONEB 10 MG/5 MG TABLET, 30 ADET, AMLONEB 10 MG/5 MG TABLET, 90 ADETCategories: Adrenergic beta-1 Receptor Agonists, Heterocyclic Compounds, 1-RingEtevritamab
go.drugbank.com/drugs/DB17211InvestigationalSynonyms: anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct, LINKER (GGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN AXylometazoline
go.drugbank.com/drugs/DB06694ApprovedXylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels. … In some countries, it is available as combination products with [ipratropium], [domiphen], or [dexpanthenol].
Mixtures: NASOVİNE DUO 0,5 MG + 0,6 MG/ML BURUN SPREYİ, ÇÖZELTİ, 1 ADET, nasic - Nasenspray für Kinder 5 mg/500 mgCategories: Adrenergic alpha-1 Receptor Agonists, Heterocyclic Compounds, 1-RingPergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnIt is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. … Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease.
Categories: Adrenergic alpha-1 Receptor Agonists, Serotonin 5-HT2 Receptor AgonistsProducts: PERGOLID-NEURAX 1 MG, PERGOLIDE EGHydrocortisone
go.drugbank.com/drugs/DB00741ApprovedInvestigationalVet approved[A188420] Hydrocortisone was granted FDA approval on 5 August 1952.[L10574] … [L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone.
Synonyms: Reichstein's substance M, (11β)-11,17,21-trihydroxypregn-4-ene-3,20-dioneInternational brands: Polcort H, Preparation H Hydrocortisone CreamOcaratuzumab
go.drugbank.com/drugs/DB17359InvestigationalOcaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
Synonyms: Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1))